Casein kinase 2 activity is a host restriction factor for AAV transduction
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2023.11.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Izabela Kraszewska und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland. Electronic addre…. Hauptthemen laut MEDLINE: Casein Kinase II, Endothelial Cells. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
So far, the mechanisms that impede AAV transduction, especially in the human heart, are poorly understood, hampering the introduction of new, effective gene therapy strategies. Therefore, the aim of this study was to identify and overcome the main cellular barriers to successful transduction in the heart, using induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iPSC-CMs), iPSC-derived cardiac fibroblasts (iPSC-CFs), and primary endothelial cells to model vector-host interactions. Through phosphoproteome analysis we established that casein kinase 2 (CK2) signaling is one of the most significantly affected pathways upon AAV exposure. Transient inhibition of CK2 activity substantially enhanced the transduction rate of AAV2, AAV6, and AAV9 in all tested cell types. In particular, CK2 inhibition improved the trafficking of AAVs through the cytoplasm, impaired DNA damage response through destabilization of MRE11, and altered the RNA processing pathways, which were also highly responsive to AAV transduction. Also, it augmented transgene expression in already transduced iPSC-CFs, which retain AAV genomes in a functional, but probably silent form. In summary, the present study provides new insights into the current understanding of the host-AAV vector interaction, identifying CK2 activity as a key barrier to efficient transduction and transgene expression, which may translate to improving the outcome of AAV-based therapies in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland. Electronic address: izabela.kraszewska@doctoral.uj.edu.pl.
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland; Doctoral School of Exact and Natural Sciences, Jagiellonian University, Krakow, Poland.
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
- CECAD Research Center, Institute for Genetics, University of Cologne, Cologne, Germany.
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland. Electronic address: agnieszka.jazwa@uj.edu.pl.
Zitieren
APA
Kraszewska, I., Sarad, K., Andrysiak, K., Kopacz, A., Schmidt, L., Krüger, M., Dulak, J., & Jaźwa-Kusior, A. (2024). Casein kinase 2 activity is a host restriction factor for AAV transduction. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2023.11.010
Vancouver
Kraszewska I, Sarad K, Andrysiak K, Kopacz A, Schmidt L, Krüger M, et al. Casein kinase 2 activity is a host restriction factor for AAV transduction. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2023.11.010
BibTeX
@article{Kraszewska2024,
author = {Kraszewska, Izabela and Sarad, Katarzyna and Andrysiak, Kalina and Kopacz, Aleksandra and Schmidt, Luisa and Krüger, Marcus and Dulak, Józef and Jaźwa-Kusior, Agnieszka},
title = {Casein kinase 2 activity is a host restriction factor for AAV transduction},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2023.11.010}
}
EUVIMED